Pfizer Animal Health announced Nov. 7 that it has opened the Pfizer Animal Health Equine Research Center and noted its commitment to innovative equine health. The center in Richland, Mich. - the culmination of a $7 million investment - expands the company's global research and development network headquarters in Kalamazoo, Mich., and serves as a worldwide hub for research and development of equine vaccines and novel therapeutics.
"The dedication of the Equine Research Center builds on the $75 million investment in the renovation and expansion of Pfizer's veterinary medicine R&D headquarters in Kalamazoo completed in 2009," said Dr. Cathy Knupp, vice president of Veterinary Medicine Research & Development for Pfizer Animal Health. "The center will support the work of a multi-disciplinary team of scientists committed to providing horse owners and the veterinarians who support them with best-in-class health solutions."
The center adds 24,000 sq. ft. of research laboratory space as well as paddock and pasture facilities. It will serve as the U.S. equine research center of excellence for a multi-disciplinary team of scientists and specialists.
"Horses, like humans, are vulnerable to new outbreaks of prevalent illnesses such as equine influenza virus and Streptococcus equi as well as to emerging diseases such as Hendra virus," said Dr. Paul Lunn, professor and head of the department of clinical sciences at Colorado State University's College of Veterinary Medicine & Biomedical Sciences. "The Pfizer Equine Research Center will help answer the urgent imperative for much needed innovation to help horses live longer, healthier lives."